Showing 1161-1170 of 21421 results for "".
- Intrathecal Morphine Versus Wound Infiltration After Pancreatoduodenectomyhttps://reachmd.com/news/intrathecal-morphine-versus-wound-infiltration-after-pancreatoduodenectomy/2487776/Key Takeaways Single-shot intrathecal morphine was noninferior to continuous wound infiltration for the primary mean pain score outcome after open pancreatoduodenectomy. Intrathecal morphine was also noninferior for mean resting pain, with lower early
- Long-Term Air Pollution Exposure Linked to Incident CKDhttps://reachmd.com/news/long-term-air-pollution-exposure-linked-to-incident-ckd/2487775/Key Takeaways Long-term residential exposure to PM2.5, PM10, NO2, and black carbon was associated with modestly higher incident CKD in the main adjusted analysis. The NO2 association was stronger among never-smokers, and NO2 and black carbon remained p
- Parent Mental Health Interventions in the NICUhttps://reachmd.com/news/parent-mental-health-interventions-in-the-nicu/2487729/Key Takeaways The review included 160 studies, 16,639 parents, and 85 meta-analysis estimates assessing anxiety, depression, stress, and trauma symptoms with validated self-report questionnaires. Anxiety improved with bonding interventions, family-centered c
- Report: Dermatology M&A Momentum Sets Sights on Independent Practiceshttps://reachmd.com/news/dermatology-ma-momentum-continues-as-buyers-chase-independent-practices/2487714/Private equity investment in dermatology continues at a rapid pace in 2026, with buyer demand remaining strong despite more than a decade of consolidation across the specialty, according to a new market update from Physician Growth Partners.
- Consensus Panel Offers First Standardized Imaging Framework for High-Risk CSCChttps://reachmd.com/news/consensus-panel-offers-first-standardized-imaging-framework-for-high-risk-cscc/2487708/A multidisciplinary panel of experts has developed consensus recommendations to help standardize staging and surveillance imaging for patients with localized cutaneous squamous cell carcinoma (cSCC), publishing the recommendations online in
- FDA Accepts sNDA for Roflumilast Cream 0.05% in Infants With ADhttps://reachmd.com/news/fda-accepts-snda-for-zoryve-cream-005-in-infants-with-atopic-dermatitis/2487703/The US Food and Drug Administration (FDA) anounced that it has accepted Arcutis Biotherapeutics' supplemental New Drug Application (sNDA) seeking to expand the indication for ZORYVE (roflumilast) cream 0.05% to include infants aged 3 to 24 months with mild to mode
- Teva Advances Anti-IL-15 Antibody Into Phase 2b for Vitiligohttps://reachmd.com/news/teva-advances-anti-il-15-antibody-into-phase-2b-for-vitiligo/2487696/Teva Pharmaceutical Industries Ltd. has announced plans to advance its investigational anti-interleukin-15 (IL-15) monoclonal antibody (TEV-'408) into a Phase 2b clinical trial for non-segmental vitiligo (NSV) in the fourth quarter of 2026 following encouraging in
- Global Survey Highlights Widespread Skin Quality Concerns and Emotional Impacthttps://reachmd.com/news/global-survey-highlights-widespread-skin-quality-concerns-and-emotional-impact/2487693/A new global survey commissioned by Galderma found that skin quality concerns are nearly universal, with 9 in 10 respondents reporting at least 1 concern during the previous month and most experiencing an average of 2 concerns.1 The survey included more than 11,000 participants
- Otsuka Reports Two-Year VISIONARY EGFR Results in IgA Nephropathyhttps://reachmd.com/news/otsuka-reports-two-year-visionary-egfr-results-in-iga-nephropathy/2487671/Key Takeaways The topline readout centered on eGFR and was described as showing statistically significant kidney-function stabilization versus placebo over two years, with evidence of improvement. VOYXACT was characterized as well tolerated, with a fav
- Meta-analysis: Topical Ivermectin, Encapsulated BPO Show Strongest Efficacy in Rosaceahttps://reachmd.com/news/topical-ivermectin-encapsulated-benzoyl-peroxide-show-strongest-efficacy-in-rosacea-network-meta-analysis/2487668/A systematic review and network meta-analysis of randomized clinical trials suggests that topical ivermectin and encapsulated benzoyl peroxide (E-BPO) provide greater efficacy than metronidazole for adults with moderate to severe rosacea.